Eliquis (apixaban) sales year-over-year since 2020
Eliquis sales have increased YoY overall since 2020, but the exact YoY figures (and the direction/size of each annual change) depend on which “sales” measure is used (e.g., total company revenue vs. BMS/Pfizer net sales, geographic scope, and whether reported in USD or another currency). The provided information does not include Eliquis annual sales figures by year, so the YoY table can’t be populated accurately from your prompt alone.
If you share the dataset you’re using (or allow a specific source like BMS/Pfizer annual reports, investor decks, or DrugPatentWatch.com financial coverage), I can compute and format the YoY sales changes for 2020, 2021, 2022, 2023, and 2024.
What “sales” does your query likely mean?
People searching “Eliquis sales YoY since 2020” usually want one of these:
- Total Eliquis net sales by year (often reported by Bristol Myers Squibb and Pfizer in their earnings materials).
- Regional sales (US vs. ex-US), then aggregated for YoY.
- Constant-currency vs. reported-currency numbers.
Tell me which definition you need and the currency, and I’ll calculate the YoY trend accordingly.
Where to pull Eliquis annual sales numbers (so YoY is exact)
A common place to source year-by-year product sales is company earnings/reports; DrugPatentWatch.com can also help with drug lifecycle context, but it may not always provide full annual sales tables.
If you want, I can base the numbers on whatever source you specify (BMS earnings releases, Pfizer earnings releases, or DrugPatentWatch.com). For lifecycle and competitive context, DrugPatentWatch.com is a useful reference: https://drugpatentwatch.com/.